Mode
Text Size
Log in / Sign up
Phase 3 Completed N=601 Randomized Quadruple-blind Treatment

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

Source: ClinicalTrials.gov NCT02974907 ↗
Enrolled (actual)
601
Serious AEs
0.8%
Results posted
Jan 2022
Primary outcomePrimary: Ocular Discomfort — 0.07; -0.04 score on a scale
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.

Outcome Measures

OutcomeResultp-value
PRIMARY
Ocular Discomfort
0.07; -0.04
PRIMARY
Corneal Fluorescein Staining
SECONDARY
Corneal Fluorescein Staining
SECONDARY
Unanesthetized Schirmer's Test
SECONDARY
Ocular Surface Disease Index (OSDI)©
SECONDARY
Tear Film Break-Up Time

Eligibility Criteria

Inclusion Criteria

  • Be at least 18 years of age;
  • Provide written informed consent;
  • Have a subject reported history of dry eye for at least 6 months
  • Have a history of use or desire to use eye drops for dry eye symptoms within 6 months

Exclusion Criteria

  • Have any clinically significant slit-lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
  • Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
  • Have ab uncontrolled systemic disease:
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02974907). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search